| Alnylam Pharmaceuticals, Inc. | $40.3b | $301.56 | +2.0% | 76.0K | |
| Ionis Pharmaceuticals, Inc. Common Stock | $12.6b | $81.81 | +2.7% | 493.3K | |
| Arrowhead Research Corporation | $11.0b | $80.70 | +0.1% | 137.3K | |
| Wave Life Sciences Ltd. Ordinary Shares | $1.3b | $6.01 | +3.7% | 223.2K | |
| CAMP4 Therapeutics Corporation Common Stock | $228.0m | $4.20 | +3.3% | 26.2K | |
| Atrium Therapeutics, Inc. Common Stock | $222.4m | $12.90 | 0.0% | 4.2K | |
| Cartesian Therapeutics, Inc. Common Stock | $221.5m | $9.31 | +0.3% | 7.9K | |
| ProQR Therapeutics N.V. Ordinary Shares | $166.5m | $1.58 | -2.2% | 242.3K | |
| Exicure, Inc. Common Stock | $20.3m | $2.67 | 0.0% | 17.8K | |
| Phio Pharmaceuticals Corp. Common Stock | $12.9m | $0.99 | 0.0% | 20.6K |